Browse drugs

…Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progre…

…. For HCC-specific mortality, higher risks were associated with Lenvatinib (aHR 9.04; 95%CI 3.36-24.3; p<0.001), Sorafenib (aHR 5.82; 95%C…

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…BTC were enrolled from five centers in China. Patients received pembrolizumab (200 mg, every 3 weeks), lenvatinib (8 or 12 mg daily), and mod…

…nefit has been obtained, the drug resistance remarkably reduced lenvatinib clinical efficacy. Here, we aimed to identify the potential mec…

…proach. We report the primary results of a neoadjuvant study of lenvatinib plus pembrolizumab in resectable MCC.Methods In this single-cen…

…e enrolled in this study to receive the combination of RC48 and lenvatinib. The primary study endpoint is objective response rate, and the…

…treatment samples and in responders.Conclusions Lenvatinib plus pembrolizumab demonstrated encouraging efficacy when used as neoadjuvant ther…

… the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the advent of immunoth…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…n 85 mg/m² every 3 weeks), lenvatinib (8 mg/day from Day 5) and Adebrelimab (1200 mg on Day 3, every 3 weeks) for 2–4 cycles. Surgery eligi…

…ompare the effectiveness and safety of HAIC in combination with lenvatinib and programmed death receptor-1 (PD-1) inhibitors (H+L+P) to th…